Article
Medicine, General & Internal
Eric Anderson, Alexis LeVee, Sungjin Kim, Katelyn Atkins, Michelle Guan, Veronica Placencio-Hickok, Natalie Moshayedi, Andrew Hendifar, Arsen Osipov, Alexandra Gangi, Miguel Burch, Kevin Waters, May Cho, Samuel Klempner, Joseph Chao, Mitchell Kamrava, Jun Gong
Summary: The study reveals that neoadjuvant chemoradiation (nCRT) is associated with the highest rate of pathologic complete response, while neoadjuvant and adjuvant chemotherapy (CTTU) is associated with the best overall survival.
Review
Oncology
M. Usman Ahmad, Christopher Javadi, George A. Poultsides
Summary: Neoadjuvant and/or perioperative therapy has emerged as a treatment tool to improve patient selection and locoregional control for resectable proximal gastric, gastroesophageal junction, and distal esophageal cancer. Treatment recommendations differ based on histologic type and tumor location. Neoadjuvant chemoradiation with concurrent taxane- or fluoropyrimidine-based chemotherapy has shown efficacy for both adenocarcinoma and squamous cell carcinoma of the distal esophagus and gastroesophageal junction.
Article
Oncology
Felix Ho, Robert J. Torphy, Chloe Friedman, Stephen Leong, Sunnie Kim, Sachin Wani, Tracey Schefter, Christopher D. Scott, John D. Mitchell, Michael J. Weyant, Robert A. Meguid, Ana L. Gleisner, Karyn A. Goodman, Martin D. McCarter
Summary: In patients with esophageal and gastroesophageal junction adenocarcinoma, induction chemotherapy before neoadjuvant chemotherapy with concurrent radiotherapy was associated with significantly improved overall survival and higher pathological complete response rate. Furthermore, in patients diagnosed from 2013 to 2015, induction chemotherapy with neoadjuvant chemotherapy and concurrent radiotherapy was also linked to a higher odds of achieving pathological complete response.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Hai-Bo Sun, Sen Yan, Xian-Ben Liu, Wen-Qun Xing, Pei-Nan Chen, Shi-Lei Liu, Peng Li, Ya-Xing Ma, Toni Lerut, Ahmed Daoud, Duo Jiang, Hai-Bo Sun
Summary: The study demonstrates that neoadjuvant chemotherapy (NAC) plus surgery prolongs overall survival (OS) and disease-free survival (DFS) and significantly decreases the rate of recurrence in patients with clinical stage II and III esophageal squamous cell carcinoma (ESCC) compared with surgery plus adjuvant chemotherapy (AC).
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Noriyuki Hirahara, Takeshi Matsubara, Shunsuke Kaji, Hikota Hayashi, Koki Kawakami, Yohei Sasaki, Satoshi Takao, Natsuko Takao, Ryoji Hyakudomi, Tetsu Yamamoto, Yoshitsugu Tajima
Summary: This study aimed to evaluate the feasibility of adjuvant chemotherapy with S-1 in patients after esophagectomy. The results showed that S-1 could be safely and continuously administered as adjuvant chemotherapy for patients with esophageal cancer regardless of neoadjuvant chemotherapy (NAC).
Article
Medicine, General & Internal
Dashan Ai, Jinjun Ye, Shihong Wei, Yunhai Li, Hui Luo, Jianzhong Cao, Zhengfei Zhu, Weixin Zhao, Qin Lin, Huanjun Yang, Xiangpeng Zheng, Jialiang Zhou, Guang Huang, Ling Li, Jiancheng Li, Zhi Zhang, Guoren Zhou, Dayong Gu, Mingyu Du, Miao Mo, HuiXun Jia, Zhen Zhang, Kuaile Zhao
Summary: This randomized clinical trial compared the efficacy and adverse events of fluorouracil, cisplatin, and carboplatin in definitive chemoradiotherapy for patients with esophageal squamous cell carcinoma (ESCC). The results showed that paclitaxel plus fluorouracil did not have superior overall survival compared to paclitaxel plus cisplatin or paclitaxel plus carboplatin regimens in locally advanced ESCC. The cisplatin group had higher rates of hematologic and gastrointestinal toxic effects.
Article
Medicine, General & Internal
Sapna P. Patel, Megan Othus, Yuanbin Chen, G. Paul Wright, Kathleen J. Yost, John R. Hyngstrom, Siwen Hu-Lieskovan, Christopher D. Lao, Leslie A. Fecher, Thach-Giao Truong, Jennifer L. Eisenstein, Sunandana Chandra, Jeffrey A. Sosman, Kari L. Kendra, Richard C. Wu, Craig E. Devoe, Gary B. Deutsch, Aparna Hegde, Maya Khalil, Ankit Mangla, Amy M. Reese, Merrick I. Ross, Andrew S. Poklepovic, Giao Q. Phan, Adedayo A. Onitilo, Demet G. Yasar, Benjamin C. Powers, Gary C. Doolittle, Gino K. In, Niels Kokot, Geoffrey T. Gibney, Michael B. Atkins, Montaser Shaheen, James A. Warneke, Alexandra Ikeguchi, Jose E. Najera, Bartosz Chmielowski, Joseph G. Crompton, Justin D. Floyd, Eddy Hsueh, Kim A. Margolin, Warren A. Chow, Kenneth F. Grossmann, Eliana Dietrich, Victor G. Prieto, Michael C. Lowe, Elizabeth I. Buchbinder, John M. Kirkwood, Larissa Korde, James Moon, Elad Sharon, Vernon K. Sondak, Antoni Ribas
Summary: This study aimed to investigate whether giving pembrolizumab both before and after surgery would improve event-free survival in patients with resectable stage III or IV melanoma. Results showed that patients who received pembrolizumab both before and after surgery had significantly longer event-free survival. Overall rating: 9 out of 10.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Editorial Material
Medicine, General & Internal
David H. Ilson
Summary: Esophageal cancer is a major cause of cancer-related illness and death worldwide, often presenting with locally advanced or metastatic disease due to lack of effective screening or early detection. Esophageal squamous-cell carcinoma is the most common histologic type globally, especially in high-incidence areas like East Asia, while adenocarcinoma dominates in the West. Surgical outcomes for esophageal squamous-cell cancer patients in 1980 highlighted the significant challenge in treating esophageal cancer.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Immunology
Qing Li, Ting Liu, Zhenyu Ding
Summary: Esophageal cancer is one of the most common cancers worldwide, especially in China. Current treatment methods have limited efficacy, necessitating the exploration of new treatment strategies. Immunotherapy has emerged as a promising approach and has been shown to significantly improve survival rates in cancer patients. Combining chemotherapy and/or radiotherapy with immunotherapy may have a synergistic antitumor effect.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Xiaokun Li, Siyuan Luan, Yushang Yang, Jianfeng Zhou, Qixin Shang, Pinhao Fang, Xin Xiao, Hanlu Zhang, Yong Yuan
Summary: This study aimed to explore the effectiveness of adjuvant therapy after trimodal therapy (neoadjuvant chemoradiotherapy and esophagectomy) in patients with thoracic esophageal squamous cell carcinoma (ESCC). The results showed that adjuvant therapy could reduce the overall survival (OS) and disease-free survival (DFS) in ESCC patients. It is not recommended for patients without nodal metastases after neoadjuvant therapy.
Article
Oncology
Glenn J. Hanna, Anne O'Neill, Kee-Young Shin, Kristine Wong, Vickie Y. Jo, Charles T. Quinn, Jennifer M. Cutler, Michelle Flynn, Patrick H. Lizotte, Donald J. Annino, Laura A. Goguen, Jason Kass, Eleni M. Rettig, Rosh K. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Megan E. Cavanaugh, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert Haddad
Summary: This study investigated the use of dual immune-checkpoint inhibition in locoregionally recurrent squamous cell carcinoma of the head and neck (SCCHN) before and after surgery. The results showed a promising response rate and suggests further evaluation of this strategy.
CLINICAL CANCER RESEARCH
(2022)
Article
Surgery
Siva W. Raja, Thomas Rice, Min E. Lu, Marie H. Semple, Eugene C. Blackstone, Sudish Murthy, Usman Ahmad, Michael J. McNamara, Andrew Toth, Hemant Ishwaran
Summary: The study aimed to identify which patients with locally advanced esophageal cancer would benefit the most from additional adjuvant therapy after neoadjuvant therapy. It was found that patients with more advanced cancer, specifically those with high nodal burden and positive margins, received the most survival benefit from adjuvant therapy.
Article
Cardiac & Cardiovascular Systems
Tiuri E. Kroese, Willemieke P. M. Dijksterhuis, Peter S. N. van Rossum, Rob H. A. Verhoeven, Stella Mook, Nadia Haj Mohammad, Maarten C. C. M. Hulshof, Mark I. van Berge Henegouwen, Martijn G. H. van Oijen, Jelle P. Ruurda, Hanneke W. M. van Laarhoven, Richard van Hillegersberg
Summary: This study evaluated the management, overall survival, and prognostic factors of esophageal cancer patients with interval distant metastases. The findings suggest that the survival outcomes of these patients are influenced by treatment strategies and prognostic factors, and are comparable to those of synchronous metastatic patients.
ANNALS OF THORACIC SURGERY
(2022)
Article
Oncology
Po-Kuei Hsu, Yi-Chen Yeh, Ling- Chien, Chien-Sheng Huang, Han-Shui Hsu
Summary: Pathologic complete lymph node regression may be an indicator of sensitivity to neoadjuvant treatment and serves as a good prognostic factor in patients with esophageal squamous cell carcinoma.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Gastroenterology & Hepatology
Yu-Tso Liao, Yu-Lin Lin, John Huang, Ji-Shiang Hung, Been-Ren Lin
Summary: This study evaluated the necessity of adjuvant chemotherapy for ypT0-2N0 rectal cancer patients. Results showed that postoperative adjuvant chemotherapy may not be required for patients downstaged by neoadjuvant therapy, especially in those without poor prognostic factors.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
(2021)